

Supply issues summary w/c 4th March 2024

Supply Issue/ Manufacturer	Resupply date	Comment
Acetazolamide (Diamox SR) 250mg modified-release capsules	OOS until 26 th February 2024.	<ul style="list-style-type: none"> Acetazolamide immediate release 250mg tablets remain available and can support an uplift in demand.
ADHD medicines	Various updates	<ul style="list-style-type: none"> See the SPS dedicated page
Adrenaline 150/ 300 /500 microgram (Emerade) auto-injectors / Bausch & Lomb UK Ltd	OOS until 16 th December 2024	<ul style="list-style-type: none"> There are currently sufficient supplies of Jext and EpiPen Junior to meet normal UK demand for adrenaline 150microgram auto-injectors
Aprepitant 125mg oral powder sachets	OOS until 16 th August 2024	<ul style="list-style-type: none"> The following alternatives remain available: Aprepitant 80mg and 125mg capsules
Benperidol (Anquil®) 250microgram tablets	OOS until 2 nd August 2024	<ul style="list-style-type: none"> Review needed by a relevant mental health specialist
Betamethasone valerate 0.1% cream and 0.1% ointment	OOS until 16 th February 2024	<ul style="list-style-type: none"> Clinicians should consider prescribing mometasone furoate 0.1% cream or 0.1% ointment.
Bismuth subsalicylate (Pepto-Bismol)	OOS until 30 th October 2024	<ul style="list-style-type: none"> Alternative medicines for acid reflux, indigestion, diarrhoea, and nausea remain available.
Bumetanide 5mg tablets	OOS until 3 rd May 2024	<ul style="list-style-type: none"> Bumetanide 1mg tablets remain available and can support increased demand. Bumetanide 1mg/5ml SF oral solution remains available but is unable to support increased demand.
Buserelin nasal spray (Suprecur) /Neon Healthcare Ltd	150micrograms OOS until 6 th December 2024 5.5mg OOS until 2 nd February 2024	<ul style="list-style-type: none"> Alternative parenteral and nasal GnRH analogues
Capsaicin 0.025% and 0.075% cream	OOS until 6 th January 2025	<ul style="list-style-type: none"> Consider if topical therapy still appropriate, unlicensed 0.025% and 0.075% cream available
Cefalexin 250mg tablets	OOS until 3 rd May 2024	<ul style="list-style-type: none"> The following products remain available and can support during this time: <ul style="list-style-type: none"> Cefalexin 250mg capsules Cefalexin 125mg/5ml oral solution

		<ul style="list-style-type: none"> ○ Cefalexin 250mg/5ml oral solution
Co-trimoxazole 40mg/200mg/5ml oral suspension sugar free	OOS until 2 nd February 2024	<ul style="list-style-type: none"> • Co-trimoxazole 80mg/400mg/5ml oral suspension remains available and can support increased demand • Where this is not suitable, unlicensed supplies of co-trimoxazole 40mg/200mg/5ml oral suspension sugar free may be sourced, lead times vary
Creon 25,000 gastro-resistant capsules	OOS until 1 st March 2024	<ul style="list-style-type: none"> • Creon 10,000 gastro-resistant capsules remain available and can support a partial increase in demand. • Alternative pancreatin preparations remain available, however, are unable to support an increase in demand.
Cyanocobalamin (Cytamen) 1mg/1ml solution for injection ampoules	Resupply date to be confirmed	<ul style="list-style-type: none"> • Clinicians should consider prescribing hydroxocobalamin 1mg/ml injection. • If this is unsuitable, advice should be sought from specialists on management options.
Diazepam 2mg/5ml oral solution sugar free	OOS until 5 th April 2024	<ul style="list-style-type: none"> • Diazepam tablets remain available. • Unlicensed diazepam 2mg/5ml oral suspension (sugar free) 'Specials' can be sourced.
Dicycloverine 10mg/5ml oral solution	OOS until 29 th March 2024	<ul style="list-style-type: none"> • If patients are able to swallow solid dosage forms and consider prescribing dicycloverine 10mg tablets if appropriate; and • Consider prescribing a liquid formulation of an alternative antispasmodic for patients unable to swallow solid dosage forms
Dioralyte oral rehydration sachets	Resupply date to be confirmed	<ul style="list-style-type: none"> • Consider the use of alternative oral rehydration treatments where stocks of Dioralyte and Dioralyte Relief are unavailable
Epilim (sodium valproate) syrup 200mg/5ml	OOS until 26 th April 2024	<ul style="list-style-type: none"> • Epilim 200mg/5ml liquid (sugar-free) remains available and can support increased demand.
FemSeven Sequi transdermal patches	OOS until 1 st January 2024.	<ul style="list-style-type: none"> • Specialist importers can source unlicensed products.
Fluoxetine (Olena) 20mg dispersible tablets	OOS until 31 st May 2024	<ul style="list-style-type: none"> • The following alternatives are available: <ul style="list-style-type: none"> ○ Capsules, including the 10mg and 20mg strengths.

		<ul style="list-style-type: none"> ○ Citalopram 40mg/mL oral drops and escitalopram (Cipralex) 20mg/mL oral drops.
Flixotide (fluticasone) 50 micrograms/dose Evohaler	OOS until 8 th March	<ul style="list-style-type: none"> • consider suitability of Flixotide 50 micrograms/dose Accuhaler, a dry powder inhaler (DPI) in patients able to use this device, and prescribe one month's supply to cover gap until the Evohaler is back in stock or • in patients on 2 puffs (100micrograms) twice daily of Flixotide 50 micrograms/dose Evohaler for whom a DPI is unsuitable, consider prescribing Flixotide 125 micrograms/dose Evohaler 1 puff twice daily, as this provides the closest dose to that currently being used or • where patients are already prescribed a Flixotide 50 micrograms/dose Evohaler and a salmeterol inhaler separately, consider prescribing Seretide 50 Evohaler as this combination inhaler delivers 50 micrograms fluticasone and 25 micrograms salmeterol
Fluticasone 400microgram/unit nasal drops	OOS until 2 nd February 2024	<ul style="list-style-type: none"> • check with pharmacy for availability of generic fluticasone propionate 400 micrograms (1mg/ml) nasal drops suspension (Aspire Pharma), where this is unavailable; • consider prescribing an alternative steroid nasal drop or spray for the treatment of nasal polyps, ensuring the patient is counselled on use and is not intolerant to any of the excipients; or • consider prescribing other steroid formulations off-label for oral ulceration and inflammation, in line with local guidance; • consider prescribing unlicensed products only where above-mentioned options are not available/appropriate. Prescribers should work with local pharmacy

		teams to ensure orders are placed within appropriate time frames as lead times may vary
Formoterol (Oxis 6 Turbohaler) 6micrograms/dose dry powder inhaler	OOS until 15 th March 2024	<ul style="list-style-type: none"> consider suitability of Flixotide 50 micrograms/dose Accuhaler, a dry powder inhaler (DPI) in patients able to use this device, and prescribe one month's supply to cover gap until the Evohaler is back in stock or in patients on 2 puffs (100micrograms) twice daily of Flixotide 50 micrograms/dose Evohaler for whom a DPI is unsuitable, consider prescribing Flixotide 125 micrograms/dose Evohaler 1 puff twice daily, as this provides the closest dose to that currently being used or where patients are already prescribed a Flixotide 50 micrograms/dose Evohaler and a salmeterol inhaler separately, consider prescribing Seretide 50 Evohaler as this combination inhaler delivers 50 micrograms fluticasone and 25 micrograms salmeterol
GLP-1 receptor agonists (semaglutide, dulaglutide, liraglutide, exenatide)	OOS until 28 th June 2024 Exenatide OOS until 27 th November 2023	<ul style="list-style-type: none"> Very limited, intermittent supplies of all GLP-1 Ras – see <u>SPS</u> website. Limited supply will only be available for existing diabetic patients
Glucagon 1mg powder for injection kit (Glucagen)	OOS until 29 th March 2024	<ul style="list-style-type: none"> Intermittent supply of GlucaGen 1mg powder for injection kit. Ogluo 0.5mg and 1mg pre-filled auto-injector pens remain available via Alliance.
Griseofulvin 125mg and 500mg tablets	OOS until 125mg 8 th March 2024. 500mg until 5 th April 2024.	<ul style="list-style-type: none"> Alternative oral antifungals remain available. The following specialist importers have confirmed they can source unlicensed griseofulvin 125mg and 500mg tablets (please note there may be other companies that can also source supplies): <ul style="list-style-type: none"> o Alium Medical o Target Healthcare

H2-antagonists/ Various brands	Various updates	<ul style="list-style-type: none"> • Please refer to the local Ranitidine Switch Protocol for use in primary care. • See here for updates on resupply dates.
HRT	Various updates – largely in stock	<ul style="list-style-type: none"> • See BMS or SPS for current availability
hydrocortisone 0.1% cream (Marlborough Pharmaceuticals Ltd)	0.1% OOS until 5 th July 2024	<ul style="list-style-type: none"> • The Dermacort SmPC states that clinical studies have confirmed that 0.1% Dermacort is equivalent to 1.0% hydrocortisone cream BP/BPC. • Both 0.1% and 1.0% hydrocortisone are classed as mildly potent topical corticosteroids. Potency of a topical corticosteroid preparation is a result of the formulation as well as the corticosteroid.
Hydrocortisone 2.5mg muco-adhesive buccal tablets sugar free / Accord Healthcare Ltd	OOS until 1 st June 2024	<ul style="list-style-type: none"> • Other over-the-counter preparations such as topical anesthetics, topical analgesics/anti-inflammatory agents and topical antimicrobial agents marketed as oral gels, mouthwashes and oral sprays remain available. • Betamethasone soluble tablets for off-label topical use in the treatment of aphthous ulcers remain available.
Hyoscine hydrobromide (Scopoderm) 1.5mg patches	OOS until 3 rd January 2025	<ul style="list-style-type: none"> • Consider other hyoscine hydrobromide formulations or • unlicensed hyoscine hydrobromide (Scopoderm) 1.5mg patches if alternative options are not suitable
Indometacin (Indocid) 100mg suppositories	OOS until 1 st March 2024	<ul style="list-style-type: none"> • Parallel imports limited supplies of are available.
Isosorbide mononitrate 40mg modified-release tablets and capsules	Various dates	<ul style="list-style-type: none"> • Where existing patients have insufficient supply to last until the re-supply date(s), prescribers should consider prescribing one of the following to make up a dose as close as possible to that taken by patient. • an alternative 40mg MR presentation, if available

		<ul style="list-style-type: none"> • a 50mg MR tablet if the 40mg MR preparation(s) are not available. • a 60mg MR tablet (which can also be halved to provide 30mg doses) if the 40mg MR preparation(s) are not available
Ketotifen 1mg/5ml oral solution sugar free	OOS until 15 th March 2024	<ul style="list-style-type: none"> • Prescribing ketotifen 1mg tablets ensuring that the patient is not intolerant to any of the excipients and is counselled on the appropriate dose; and • Where the above is not suitable, consider prescribing unlicensed products only where licensed alternatives are not appropriate. Prescribers should work with local pharmacy teams to ensure orders are placed within appropriate time frames as lead times may vary.
Lamotrigine 5mg dispersible tablets (Teva UK Ltd)	OOS until 16 th February 2024.	<ul style="list-style-type: none"> • Lamictal 2mg and 5mg dispersible tablets remain available but cannot fully support the gap in the market • A number of Specials manufacturers are able to produce unlicensed 5mg/5ml and 25mg/5ml oral suspension (including sugar-free formulations) • Where the above options are not suitable, unlicensed supplies of Lamictal 5mg dispersible tablets may be sourced, lead times vary.
Lamotrigine tablets (Accord-UK Ltd)	OOS until 30 th April 2024	<ul style="list-style-type: none"> • Alternative generic and branded lamotrigine tablets of all strengths remain available and can support the increased demand.
Levomepromazine 25mg and 50mg tablets (Morningside Healthcare Ltd)	OOS until 8 th March 2024.	<ul style="list-style-type: none"> • Nozinan 25mg tablets remain available from Neuraxpharm UK Limited and are able to fully support demand. Stock is available via Phoenix and Alliance Healthcare. • Levoro) 5mg/ml oral solution remains available from Galvany Pharma Limited and are able to support with covering demand. Retail/community pharmacies can order from Alliance Healthcare.

Lidocaine 1% and 2% with adrenaline 100micrograms/20ml / Aspen Pharma Trading Ltd	OOS until April 2024 (1%) and May 2024 (2%)	<ul style="list-style-type: none"> Alternative local anaesthetic with adrenaline products is available, but care needed with dose of adrenaline
Medroxyprogesterone 200mg tablets	OOS until 5 th April 2024.	<ul style="list-style-type: none"> Medroxyprogesterone (Provera) 100mg tablets remain available and can support an uplift in demand
Methadone 5mg tablets	OOS until 31 st May 2024	<ul style="list-style-type: none"> consider: prescribing methadone 1mg/ml oral solution; prescribing unlicensed products only where licensed alternatives are not appropriate. Prescribers should work with local pharmacy teams to ensure orders are placed within appropriate time frames as lead times may vary (see supporting information); or
Midazolam (Epistatus) 2.5mg/0.25ml and 10mg/1ml oromucosal solution pre-filled oral syringes	2.5mg /0.25ml OOS until 1 st March 2024. 10mg/1ml OOS until 26 th January 2024	<ul style="list-style-type: none"> Consider prescribing midazolam (Buccolam or the generic) 2.5mg/0.5ml or Buccolam 10mg/2ml oromucosal solution pre-filled oral syringes where appropriate.
Nadolol 80mg tablets	OOS until 3 rd May 2024	<ul style="list-style-type: none"> Alternative beta-blockers remain available and can support increase demand.
Octreotide (Olatuton) 10mg, 20mg and 30mg powder and solvent for prolonged-release suspension for injection	OOS until 28 th June 2024	<ul style="list-style-type: none"> Secondary care will select alternative.
Olanzapine (Zypadhera) 210mg, 300mg and 405mg powder and solvent for prolonged release suspension for injection vials	OOS until 8 th February 2024	<ul style="list-style-type: none"> Review current stockholding of Zypadhera 210 mg, 300mg and 405mg powder and solvent for prolonged release suspension for injection. Only order more where current supplies are insufficient for patients scheduled to have a dose before early February 2024 to ensure the maximum number of patients can receive treatment during this time; Use an alternative strength of Zypadhera injection (if available) to administer the prescribed dose if the appropriate strength is not available
Ophthalmic preparations	Various updates	<ul style="list-style-type: none"> See here for updates on resupply dates.

Oral contraceptive tablets	Various updates when applicable	<ul style="list-style-type: none"> See here for more information.
Oxcarbazepine 150mg and 300mg tablets (Viatris)	OOS until 25 th March 2024	<ul style="list-style-type: none"> Oxcarbazepine 300mg tablets (Morningside) remain available and can support increased demand. Oxcarbazepine 150mg tablets (Trileptal) remain available, however, cannot support the full increase in demand.
Oxybutynin 5mg modified-release tablets	OOS until 5 th April 2023	<ul style="list-style-type: none"> Review patients to determine if this is still the most suitable therapy. Where appropriate, consider switching to (or re-trialling) immediate release oxybutynin tablets or oral solution, at the same total daily dose, but administered in divided doses – dose re-titration may be needed, based on symptoms and tolerability or If above options are not suitable, consider use of another anticholinergic agent
Paracetamol Suppositories	OOS 125mg until 27 th May 2024. 250mg until 3 rd June 2024. 60mg OOS until 5 th April 2024.	<ul style="list-style-type: none"> The following Licensed products remain available 120mg, 240mg, 500mg and 1000mg suppositories. Unlicensed paracetamol suppositories are available from specialist's importers.
Permethrin 5% cream	OOS until 29 th February 2024	<ul style="list-style-type: none"> Unlicensed permethrin 5% cream may be sourced.
Pethidine 50mg tablets	OOS until 5 th April 2024	<ul style="list-style-type: none"> The following specialist importers have confirmed they can source unlicensed Pethidine 50mg tablets (please note there may be other companies that can also source supplies): <ul style="list-style-type: none"> ○ Mawdsley's ○ BAP Pharma
Phenytoin sodium 100mg capsules (Accord)	OOS until 31 st December 2025.	<ul style="list-style-type: none"> Phenytoin sodium 100mg capsules (Flynn Pharma) remain available and can support an uplift in demand.
Phosphate Sandoz effervescent tablets	OOS until 29 th March 2024	<ul style="list-style-type: none"> Consider dietary replacement, with advice from a dietician if required; Consider prescribing unlicensed sodium acid (dihydrogen) phosphate

		<p>1mmol in 1ml oral solution from Specials manufacturers or unlicensed imports of Phosphate Phebra (16.1mmol phosphate) effervescent tablets. Ensure that the patient is not intolerant to any of the excipients and is counselled on the appropriate dose (and volume) required. Prescribers should work with local pharmacy teams to ensure orders are placed within appropriate time frames as lead times may vary</p>
Prednisolone 5mg/5ml oral solution unit dose	OOS until 15 th March 2024	<ul style="list-style-type: none"> • Prednisolone 5mg soluble tablets, rounding to the nearest 5mg dose where appropriate; or • prednisolone 1mg/1ml oral suspension (special order).
Pristinamycin (Pyostacine) 500mg tablets	Resupply date to be confirmed	<ul style="list-style-type: none"> • Pristinamycin, an unlicensed antibiotic medicine, is currently in limited supply with no known date for resolution
Progesterone (Crinone) 8% vagina gel and Progesterone (Lutigest) 100mg vaginal tablets	OOS until 29 th December 2023.	<ul style="list-style-type: none"> • Consider prescribing alternative progesterone products for supplementation
Rasagiline 1mg tablets	Resupply date to be confirmed	<ul style="list-style-type: none"> • Rasagiline 1mg tablets are in limited supply with a full resupply date to be confirmed. • Unlicensed supplies of rasagiline 1mg tablets may be sourced, lead times vary.
Rifampicin 150mg capsules	OOS until 29 th March 2024.	<ul style="list-style-type: none"> • Rifampicin 100mg/5ml oral suspension. This can support an uplift in demand. • Rifampicin 300mg capsules remain available.
Salbutamol 2.5mg/2.5ml and 5mg/2.5ml nebuliser liquid unit dose vials	Lead times may vary	<ul style="list-style-type: none"> • Salbutamol 2.5mg/2.5ml and 5mg/2.5ml nebuliser liquid is in very limited supply with a resolution date to be confirmed. • Unlicensed supplies of salbutamol nebuliser liquid have been sourced, lead times vary. • Alternative beta2-agonists for nebulisation remain available,

		<p>however, they cannot support an increase in demand.</p> <ul style="list-style-type: none"> • Additional guidance will be issued shortly.
Sando-K (potassium chloride 600mg and potassium bicarbonate 400mg [total potassium 12mmol] effervescent tablets	OOS until 23 rd March 2024	<ul style="list-style-type: none"> • Consider dietary replacement for mild hypokalaemia, seeking advice from dieticians if required; • Consider prescribing potassium chloride 600mg modified release tablets, if patient is able to swallow solid dosage forms, is able to follow instructions for administration, and is not intolerant to any of the excipients, ensuring they are counselled on the appropriate dose required; • Consider prescribing unlicensed supply of potassium chloride 75mg/ml oral solution or Chlorvescent effervescent tablets where licensed alternatives are not appropriate. Ensure that the patient is not intolerant to any of the excipients and is counselled on the appropriate dose (and volume) required. Prescribers should work with local pharmacy teams to ensure orders are placed within appropriate time frames as lead times may vary
Senokot 12 Years Plus syrup (containing 7.5mg/5ml sennosides)	OOS until 8 th March 2024	<ul style="list-style-type: none"> • In patients who can swallow solid oral dosage forms, senna 7.5mg tablets are licensed for use in adults and children over 12 years. • For patients who are unable to swallow a solid dosage form, alternative laxatives formulated as liquids (e.g., sodium picosulfate, dosusate sodium) or powder for oral solution (e.g., macrogol products, sodium picosulfate) are available.
Somatropin (Genotropin MiniQuick) 1.4mg powder and solvent for solution for injection pre-filled disposable devices and Somatropin (Genotropin GoQuick) 5.3mg powder and solvent for	OOS until 16 th February 2024	<ul style="list-style-type: none"> • Refer patients to their specialist for review and a switch to an appropriate alternative.

solution for injection pre-filled, multi-dose pens		
Strontium ranelate 2g granules sachets sugar free	OOS until 29 th March 2024	<ul style="list-style-type: none"> Alternative treatments used in osteoporosis remain available.
Sytron (sodium feredetate – iron 27.5mg/5ml) oral solution sugar free	OOS until 4 th July 2025	<ul style="list-style-type: none"> Consider whether this particular iron salt is preferred, and if deemed necessary, prescribe this product generically (sodium feredetate 27.5mg/5ml oral solution sugar free), considering appropriateness of use as the available products are classified as food supplements (see alternatives below); or Consider prescribing an alternative iron salt in liquid formulation that is classified as a medicinal product, ensuring the patient has no documented intolerance to that salt and counselling them/carer on dose to be administered; and
Topiramate tablets	OOS until 22 nd March 2024	<ul style="list-style-type: none"> Other manufacturers remain in stock of topiramate tablets and can support increased demand.
Triamcinolone hexacetonide 20mg/1ml suspension for injection ampoules	Resupply date to be confirmed	<ul style="list-style-type: none"> Clinicians should consider prescribing an alternative steroid injection during this time.
Tresiba (insulin degludec) FlexTouch 100units/ml solution for injection 3ml pre-filled pens	OOS until 31 st December 2024.	<ul style="list-style-type: none"> Tresiba Penfill (Insulin degludec) 100units/ml solution for injection 3ml cartridges remain available and can support the increased demand.
Valganciclovir (Valcyte) 250mg/5ml oral solution	OOS until 29 th February 2024.	<ul style="list-style-type: none"> Consider prescribing valganciclovir 450mg tablets as a first line option to deliver full doses, where appropriate consider prescribing unlicensed valganciclovir 250mg/5ml oral suspension available from Specials manufacturers or unlicensed imports of valganciclovir 250mg/5ml oral solution during this period

Varenicline (Champix) 0.5mg and 1mg tablets/ Pfizer	Resupply date to be confirmed	<ul style="list-style-type: none"> No smoking cessation products should be prescribed in primary care
Vokanamet (Canagliflozin 50mg / Metformin 1g tablets)	OOS until 17 th May 2024.	<ul style="list-style-type: none"> Use alternative strength combination product when available. When the alternative combination product is not available, individual constituents will need to be prescribed separately

Discontinuations

Supply Issue/ Manufacturer	Date	Comment
Co-magaldrox (Maalox and Maalox Plus) oral suspensions sugar free	22 nd January 2024	<ul style="list-style-type: none"> Alternative antacids for the treatment of dyspepsia remain available. Consult the BNF for options.
Ethinylestradiol tablets	date to be confirmed	<ul style="list-style-type: none"> Specialist importers can source unlicensed products. Lead times may vary.
Exenatide (Byetta) 5microgram/0.02ml and 10microgram/0.04ml solution for injection	31 st March 2024	<ul style="list-style-type: none"> Please refer to the National Patient Safety Alert for information and advice on alternatives.
Hydrogen Peroxide 3%, 6% and 9% solution	24 th November 2023	<ul style="list-style-type: none"> The following specialist importers have confirmed they can source unlicensed hydrogen peroxide solution 3% (please note there may be other companies that can also source supplies): Alium
Mizolastine 10mg modified-release tablets	26 th April 2024	<ul style="list-style-type: none"> Alternative non-sedating antihistamines remain available.
Norditropin (somatropin) NordiFlex 5mg/1.5ml, 10mg/1.5ml and 15mg/1.5ml solution	26 th February 2024	<ul style="list-style-type: none"> Proactively identify all patients on these products and refer them to their specialist prescribing centre for review and switching to Omnitrope
Pancrease HL gastro-resistant capsules	10 th November 2023	<ul style="list-style-type: none"> Alternative high strength pancreatin preparations remain

		available and will be able to support increased demand.
Testosterone 50mg/5g transdermal gel unit dose tube	29 th December 2023	<ul style="list-style-type: none"> consider prescribing an alternative testosterone gel, ensuring that the patient is not intolerant to any of the excipients and is counselled on the appropriate dose and how to administer it